ROS1: ROS Proto-oncogene 1
Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer - ScienceDirect
What Is ROS1-Positive Lung Cancer? | Massive Bio
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers - ScienceDirect
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials - The Lancet Oncology
Caveolin-1 Regulates Endothelial Adhesion of Lung Cancer Cells via Reactive Oxygen Species-Dependent Mechanism | PLOS ONE
ROS1 - Wikipedia
Recent Advances in Targeting ROS1 in Lung Cancer - ScienceDirect
Resveratrol Induces Premature Senescence in Lung Cancer Cells via ROS-Mediated DNA Damage | PLOS ONE
Frontiers | Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
ROS in cancer therapy: the bright side of the moon | Experimental & Molecular Medicine
ROS1-dependent cancers — biology, diagnostics and therapeutics | Nature Reviews Clinical Oncology
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 | NEJM
ROS1 and Lung Cancer | American Lung Association
Most frequent ROS1 fusion described proteins in lung cancer (adapted... | Download Scientific Diagram
More Choices to Treat Lung Cancer | Cancer Today
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial - The Lancet Oncology
![PDF] Zeroing in on ROS1 Rearrangements in Non–Small Cell Lung Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1833bc15a861f5f020a9b9b360aab6055f53bdd6/2-Figure1-1.png "PDF] Zeroing in on ROS1 Rearrangements in Non–Small Cell Lung Cancer | Semantic Scholar")
PDF] Zeroing in on ROS1 Rearrangements in Non–Small Cell Lung Cancer | Semantic Scholar
Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies - RSC Advances (RSC Publishing)
Metabolic Reprogramming of Branched-Chain Amino Acid Facilitates Drug Resistance in Lung Cancer----Chinese Academy of Sciences
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer | NEJM
ALK and ROS1 - Disease Drivers in Cancer | Cell Signaling Technology
GRACEcast-141_Lung_Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 - YouTube
